Merck & Co., Inc.
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Daiichi Sankyo (3 DXd ADC Oncology Programs) by Year
Daiichi Sankyo (3 DXd ADC Oncology Programs) — Current payables / liabilities to partner ($M) ($M)
Merck Daiichi Sankyo (3 DXd ADC Oncology Programs): $113M in FY2025, down 86.2% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-Q (filed 2026-08-07) ↗
Reported in Form 10-Q / 10-K Note 3/4 Collaborative Arrangements.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Daiichi Sankyo (3 DXd ADC Oncology Programs) — Current payables / liabilities to partner ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 113 | -86.2% | Form 10-Q (filed 2026-08-07) ↗ |
| FY2024 | Dec 31, 2024 | 817 | +2.1% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 800 | – | Form 10-K (filed 2025-02-25) ↗ |
Cite this data
StockData. (2026). Merck Daiichi Sankyo (3 DXd ADC Oncology Programs) ($M), annual FY2023–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab-daiichisankyo-ap-cur
See every metric in the Merck KPI table. Data updated Oct 26, 2026.
See a number that looks wrong?